OpenNashPodcasts

Person

Scott Cleve

Scott Cleve is a regulatory affairs and technology specialist who spoke on the Business Of Biotech podcast about how drug companies prepare and send regulatory submissions to health authorities, including FDA and EMA. He began his career as a consultant at Anderson Consulting, which became Accenture.

Scott Cleve described how submissions moved from paper in boxes in the late 1990s to electronic files, and said 80 to 90 percent of the information is still sent as PDFs. He also covered COVID's effect on agency timelines, and how bluebird bio is connecting its clinical, regulatory and promotion systems.

1 episodes · 24 quoted claims

Scott Cleve began his career as a consultant at Anderson Consulting, which became Accenture.

“my first consulting gig was at Anderson Consulting, which is now Accenture.”

Business Of Biotech · 0:01:36

In the late 1990s and early 2000s, drug companies shipped regulatory submissions to FDA and EMA as paper in boxes, according to Scott Cleve.

“back in the late 90s, early aughts, everyone had their picture with the pile of boxes that they were shipping off to FDA or EMA”

Business Of Biotech · 0:04:06

Scott Cleve says electronic submissions are gathered, organized, linked for review and sent to the agency through a gateway.

“you gather all of this data and information, you organize it appropriately, you connect it for agency review, and you essentially transmit it through a gateway to the agency.”

Business Of Biotech · 0:04:35

Scott Cleve says 80 to 90 percent of the information in regulatory submissions is still sent as electronic paper documents such as PDFs.

“we're still transmitting electronic paper to the agency for 80 or 90 % of the information we want to convey in a submission.”

Business Of Biotech · 0:08:22

Scott Cleve says Europe's SPOR and IDMP requirements are pushing submissions toward more granular, structured data.

“when you look at Europe's requirements with SPOR and IDMP, we're starting to get more granular.”

Business Of Biotech · 0:09:00

Scott Cleve cited wearable devices as a new source of real-world evidence that companies can give to health authorities.

“now we have your watch or a wristband or a necklace or patches that can give you information.”

Business Of Biotech · 0:07:03

Scott Cleve says the COVID pandemic moved agency resources to vaccines and tests, causing timeline shifts for other products.

“with COVID, we saw obviously there's a pandemic, so that gets raised to the top of the priority list”

Business Of Biotech · 0:10:59

Scott Cleve says the ICH created a general platform for drug development requirements that led to the Common Technical Document format.

“we have ICH, which frankly provided a nice general platform for requirements for drug development that many countries across the world follow, which led to the common technical document”

Business Of Biotech · 0:13:22

Scott Cleve says a consortium of health authorities including Australia, Singapore, Canada and Switzerland reviews drug dossiers together.

“So we have the consortium with, I think, Australia, Singapore, Canada, and Switzerland to review dossiers together.”

Business Of Biotech · 0:18:12

Scott Cleve says submission teams often repackage 90 to 95 percent of the same information for different health authorities.

“Because often we're repackaging 90 % to 95 % of the same information in slightly different ways for different health authorities.”

Business Of Biotech · 0:18:48

Scott Cleve says FDA issued several regulations and guidance documents on gene therapy in the year before the interview.

“within the last year, you've seen several regulations and guidance documents from FDA come out about gene therapy, helping set the guardrails of what they expect”

Business Of Biotech · 0:22:01

Scott Cleve says regulatory inspections often occur at clinical trial sites that are hospitals, which COVID made harder to schedule.

“So oftentimes the inspections will happen at our clinical sites and, you know, at times those were hospitals.”

Business Of Biotech · 0:25:12

Scott Cleve says bluebird bio moved from in-person meetings to fully remote work about ten months before the interview.

“we shifted from in a very in-person meeting interaction style at Bluebird to a completely remote one based on virtual technology.”

Business Of Biotech · 0:28:01

Scott Cleve said bluebird bio had a PDUFA date that week for its multiple myeloma product, co-developed with BMS.

“this week, we have a PDUFA date coming up for our multiple myeloma product that we're co-developing with BMS.”

Business Of Biotech · 0:29:46

Scott Cleve said bluebird bio's adrenal leukodystrophy product was under review in Europe, with a response expected later that year.

“we are currently under review in Europe for our adrenal leukodystrophy product.”

Business Of Biotech · 0:29:46

Scott Cleve said bluebird bio planned two FDA filings in the second half of the year and a sickle cell drug filing the following year.

“second half of the year, we have two filings for FDA and then next year our sickle cell drug will be filed.”

Business Of Biotech · 0:30:25

Scott Cleve believes FDA still leads in setting precedent for drug review data expectations, though EMA, Health Canada and PMDA might disagree.

“in terms of setting precedent in terms of drug review expectations for information and data, I think FDA is still leading the way.”

Business Of Biotech · 0:17:36

Scott Cleve says written-only agency feedback during COVID meant companies had to ask very specific questions because follow-ups were not possible.

“the questions need to be very specific and targeted to what we want to know, because if we're getting written feedback, there's not an opportunity for a follow-up question”

Business Of Biotech · 0:24:40

Scott Cleve advises early-stage companies to use templates, standards and a document management system so publishing teams can assemble submissions.

“that you emphasize the need for templates and standards, and then having folks store those into a doc management system”

Business Of Biotech · 0:32:01

Scott Cleve says errors found at the publishing step force teams to restart authoring and review, lengthening timelines.

“as your documentation and data get to that publishing step, if it's not correctly formatted, if there are content errors when it's reviewed at that time, now you go back and start that authoring review process again”

Business Of Biotech · 0:33:22

Scott Cleve described a past company that stored its company address in 14 different systems, with varying values.

“a past company had 14 places where the company address was a piece of master data.”

Business Of Biotech · 0:35:12

Scott Cleve said bluebird bio is connecting its clinical, regulatory and advertising and promotion systems around a consistent set of metadata.

“our ETMS system connects to our regulatory information management system, to our ad promo system.”

Business Of Biotech · 0:35:12

Scott Cleve said bluebird bio uses one vendor across its clinical, regulatory and commercial organizations to build consistent systems.

“we have one vendor that works throughout our clinical, regulatory, commercial organizations”

Business Of Biotech · 0:37:09

Scott Cleve says using vendors' out-of-the-box products reduces testing and revalidation because there is less customization.

“if it's built into their product there's less testing and revalidation we have to do because we're doing less customizations or fewer configurations”

Business Of Biotech · 0:37:48